Ahmad Hudoyo
Pulmonology Department, School of Medicine, University of Indonesia, Indonesia University Campus, Salemba street, Jakarta, Indonesia

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

Gejala Klinis Neurologis dan Gambaran CT Scan Otak Pasien Kanker Paru Karsinoma Bukan Sel Kecil Metastasis ke Otak di Rumah Sakit Persahabatan YULIANTI, DIAN; SYAHRUDDIN, ELISNA; HUDOYO, AHMAD; ICKSAN, AZIZA
Indonesian Journal of Cancer Vol 4, No 1 (2010): Jan - Mar 2010
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Brain is one of the common sites of distant metastasis in patients of lung cancer, and incidens of brain metastasis in lung cancer is considered high. In Non-small Cell lung cancer guide line, brain CT done if the neurological symptom occured. Therefore analysis of diagnostic approach related to brain metastases is needed. Prospective analysis of 35 patients newly diagnosed cases of brain metastases in NSCLC. Cross sectional study with additional analysis to find relationship of clinical symptom to result of CT brain over periode July 2008-August 2009 in Persahabatan Hospital. Data were analysed as regards to the presence/absence of neurogical symtomps. Prognostic approach was applied to analyze survival rate.We found that 85,7% patients brain metastases with neurological symptomatic and 14,3% asymptomatic. Five (14,3%) patients with more than one neurologycal symptoms. Depend on stage and cell type of which 27 (77,1%) with adenocarcinoma, 21 (62,9%) with T4, 17 (48,6%) N0 and patients with soliter nodule 8 (22,9%). There’s no correlation between neurologycal symptom and brain metastases. Median survival time of lung cancer patients with brain metastases are 11 month. The majority lung cancer patients with brain metastasis have neurological symptoms. The most brain metatases found in patient with adenocarcinoma, T4 and N0. Median survival was increased in treated patients Keywords: Lung cancer, NSCLC, Brain metastases, Neurological symptoms
Ekspresi Protein Gen p53 yang Bermutasi pada Jaringan Sediaan Blok Parafin Kanker Paru Karsinoma Bukan Sel Kecil HANAFI, ARIF R; SYAHRUDDIN, ELISNA; HUDOYO, AHMAD
Indonesian Journal of Cancer Vol 4, No 3 (2010): Jul - Sep 2010
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

The tumor supressor gen p53 mutation encodes a protein that inhibits programmed cell death (apoptosis). The protein is expressed in basal cells in normal human epithelium, but no data are available on the frequency or clinical importance of its expression in carcinoma. We studied p53 mutation protein expression in post surgery tissues of patients with non-small cell lung carcinoma (NSCLC) and evaluated the correlation between protein expressions with prognosis of diseases. We have performed a retrospective study using 43 parafin block samples of NSCLC patients who were underwent surgery in Persahabatan Hospital during 1997 to 2008. The p53 mutation protein expression were analyzed by immunohystochemical method using a monoclonal antibody specific for p53 mutation protein. The possibility that p53 mutation expression correlated with survival was investigated with the log-rank test Kaplan Meier. Patients characteristic we found male 25/43 (58.1%) female 18/43 (41.9%) with mean age 56.19 + 8.3 y.o and mostly age 40 to 60 y.o 33/43 (76.7%). Number of smoker patiens were 31/43 (72.1%). We also detected p53 mutation protein in 16/43 (37,2%) in NSCLC tissues. Regarding histopatology types were 9/18 (50%) in squamous-cell carcinomas and 7/25 (28%) in adenocarcinomas. The corellation between positive p53 mutation protein expressions with pathological staging was significant p 0,004, according to T status T1-T2 62,5% and T3-T4 23,8% have had positive p53 mutation protein. Favorable prognostic significance of p53 mutation in patients with NSCLC stage I – II, patients in the positive p53 mutataion survived longer than those in negative with respective median survival durations 28 and 18 months p 0,019. Adenocarcinomas type with p53 mutation have had median survival 11 months compared with squamose cell carcinomas 14 months.
Masalah Kanker Paru pada Usia Lanjut Putra, Andika Chandra; Nurwidya, Fariz; Andarini, Sita; Zaini, Jamal; Syahruddin, Elisna; Hudoyo, Ahmad; Jusuf, Anwar
Cermin Dunia Kedokteran Vol 42, No 11 (2015): Kanker
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (130.087 KB) | DOI: 10.55175/cdk.v42i11.948

Abstract

Kanker paru masih menjadi masalah kesehatan yang sulit diatasi bukan saja karena meningkatnya jumlah perokok di Indonesia tetapi juga disebabkan tingginya mortalitas dan morbiditas penderita. Beberapa panduan pengobatan merekomendasikan penanganan multimodalitas. Tatalaksana kanker paru cenderung tidak optimal pada usia lanjut padahal hampir separuh penderita kanker paru berusia di atas 65 tahun. Pasien kanker paru berusia lanjut sering memiliki penyakit komorbid, status tampilan buruk serta risiko toksisitas terapi tinggi. Tulisan ini merupakan tinjauan pustaka tatalaksana kanker paru pada usia lanjut.Lung cancer remains a health problem in Indonesia because of increase of young smokers and its high mortality and morbidity. There is a tendency of inadequate management of lung cancer among elderly patients despite fact that almost half of lung cancer patients aged over 65 years. Lung cancer management is still challenging and need comprehensive approach since older patients are more likely to have decreased functional reserve which limit their ability to undergo surgery or receive chemotherapy. Several guidelines recommended multimodality treatment. Ageing is also associated with increased co-morbid medical conditions that could exacerbate and influence outcome. This article will discuss treatment of lung cancer in elderlies.